US Patent No. 9,464,328

Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and lfe-side colon cancer disease
Oct 12, 2016

The University of Notre Dame has been awarded US Patent No. 9,464,328, "Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and lfe-side colon cancer disease."


Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.

Jun
27
Sponsored by
Roche

This webinar will present data from the FLAURA trial and show the clinical utility of liquid biopsy in identifying non-small-cell lung cancer (NSCLC) patients who may benefit from targeted TKI therapies. 

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.